Symptomtext
No additional AE reported.; Caller is a medical assistant calling to report an adverse event for M-M-R II, VAQTA, and VARIVAX. Caller reports that the patient was administered all three vaccines on 13JUL2022, after they were exposed to a temperautre excursion.; This spontaneous report has been received from a medical assistant and refers to a patient of unknown gender and age. The patient's pertinent medical history, concurrent conditions, concomitant medications, and previous drug reactions or allergies were not reported. On 13-JUL-2022, the patient was vaccinated with improperly storage dose of measles, mumps, and rubella (Wistar RA 27-3) Virus Vaccine, Live (rHA) (M-M-R II) injection (lot number U022983 which has been verified to be valid, expiration date reported and validated as 22-JUL-2023), hepatitis A vaccine, inactivated (VAQTA) injection (lot number U038841 which has been verified to be valid, expiration date reported and validated as 06-MAR-2023), and varicella virus vaccine live (Oka/Merck) (VARIVAX) injection (lot number W002599 which has been verified to be valid, expiration date reported and validated as 24-JAN-2024). All of the vaccines were administered at a dose of 0.5 milliliters (ml) as prophylaxis (strengths, routes of administration, and anatomical sites of injection were not reported). The administered dose of measles, mumps, and rubella (Wistar RA 27-3) virus vaccine, live (rHA) (M-M-R II) and hepatitis A vaccine, inactivated (VAQTA) were stored at a temperature of 65 degrees Fahrenheit (F), during a time frame of 17 hours; the dose of varicella virus vaccine live (Oka/Merck) (VARIVAX) was stored at a temperature of 67 degrees F, during a time frame of 17 hours (product storage error). There was no previous temperature excursion No additional adverse events were reported in the patient.